Category · consumer health
Cough and cold, OTC
Mass-market promo intensity rose 6 points in early 2026. The pharmacy premium tier is largely holding.
Recent signals
All news →- Earnings analysis
Reckitt Q1 2026: Core LFL +1.3% as soft cold and flu season drags, FY guidance maintained
Reckitt held Q1 2026 trading update on April 22, 2026 with Core LFL net revenue growth of 1.3% (3.1% excluding seasonal OTC). Emerging Markets grew 7.6% LFL to £1,087m. Mead Johnson Nutrition fell 2.7% LFL. FY 2026 guidance reaffirmed at 4 to 5% Core LFL. £1 billion share buyback continues with £669m completed by April 17.
Reckitt IR (Q1 2026 trading update) · 3w ago
Cough and cold, OTC weekly
Get cough and cold, otc intelligence in your inbox
Every Tuesday morning. The week's signals, outlooks, and opinion pieces tagged cough and cold, otc.